| Oct 28 |
EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema
|
| Oct 24 |
EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYUTM for the Treatment of Wet Age-Related Macular Degeneration
|
| Oct 23 |
ANI Pharmaceuticals price target raised to $62 from $60 at Truist
|
| Sep 4 |
EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors
|
| Aug 29 |
EyePoint Pharmaceuticals: After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)
|
| Aug 27 |
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
|
| Aug 10 |
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported And Analysts Have Been Cutting Their Estimates
|
| Aug 9 |
Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 37% Discount?
|
| Aug 8 |
EyePoint Pharmaceuticals files for $400M mixed securities shelf
|
| Aug 8 |
EyePoint Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
|
